{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T10:04:19Z","timestamp":1771063459225,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["ATU57495534"],"award-info":[{"award-number":["ATU57495534"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Protease inhibitors are among the most powerful antiviral drugs. However, for SARS-CoV-2 only a small number of protease inhibitors have been identified thus far and there is still a great need for assays that efficiently report protease activity and inhibition in living cells. Here, we engineer a safe VSV-based system to report both gain- and loss-of-function of coronavirus main protease (M<jats:sup>pro<\/jats:sup>\/3CLpro\/Nsp5) activity in living cells. We use SARS-CoV-2 3CLpro in this system to confirm susceptibility to known inhibitors (boceprevir, GC376, PF-00835231, and PF-07321332\/nirmatrelvir) and reevaluate other reported inhibitors (baicalein, ebselen, carmofur, ethacridine, ivermectin, masitinib, darunavir, and atazanavir). Moreover, we show that the system can be adapted to report both the function and the chemical inhibition of proteases from different coronavirus species as well as from distantly related viruses. Together with the fact that live cell assays also reflect compound permeability and toxicity, we anticipate that this system will be useful for both identification and optimization of additional coronavirus protease inhibitors.<\/jats:p>","DOI":"10.1038\/s42003-022-03277-0","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T10:03:29Z","timestamp":1651053809000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["A VSV-based assay quantifies coronavirus Mpro\/3CLpro\/Nsp5 main protease activity and chemical inhibition"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8148-9490","authenticated-orcid":false,"given":"Emmanuel","family":"Heilmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Costacurta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3169-5322","authenticated-orcid":false,"given":"Stephan","family":"Geley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyad Arad","family":"Mogadashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre","family":"Volland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Rupp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9034-9112","authenticated-orcid":false,"given":"Reuben Stewart","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5825-7237","authenticated-orcid":false,"given":"Dorothee","family":"von Laer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,27]]},"reference":[{"key":"3277_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41586-020-2577-1","volume":"586","author":"L Riva","year":"2020","unstructured":"Riva, L. et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature 586, 113\u2013119 (2020).","journal-title":"Nature"},{"key":"3277_CR2","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.arcmed.2020.04.018","volume":"51","author":"B Sayad","year":"2020","unstructured":"Sayad, B., Sobhani, M. & Khodarahmi, R. Sofosbuvir as repurposed antiviral drug against COVID-19: why were we convinced to evaluate the drug in a registeredapproved clinical trial? Arch. Med. Res. 51, 577\u2013581 (2020).","journal-title":"Arch. Med. Res."},{"key":"3277_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18096-2","volume":"11","author":"W Vuong","year":"2020","unstructured":"Vuong, W. et al. Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nat. Commun. 11, 4282 (2020).","journal-title":"Nat. Commun."},{"key":"3277_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-77700-z","volume":"10","author":"G Bolcato","year":"2020","unstructured":"Bolcato, G., Bissaro, M., Pavan, M., Sturlese, M. & Moro, S. Targeting the coronavirus SARS-CoV-2: computational insights into the mechanism of action of the protease inhibitors lopinavir, ritonavir and nelfinavir. Sci. Rep. 10, 20927 (2020).","journal-title":"Sci. Rep."},{"key":"3277_CR5","doi-asserted-by":"crossref","unstructured":"Hung, H. C. et al. Discovery of M protease inhibitors encoded by SARS-CoV-2. Antimicrob. Agents Chemother. 64, e00872\u201320 (2020).","DOI":"10.1128\/AAC.00872-20"},{"key":"3277_CR6","doi-asserted-by":"crossref","unstructured":"Gao, X. et al. Crystal structure of SARS-CoV-2 papain-like protease. Acta Pharm. Sin. B 11, 237\u2013245 (2020).","DOI":"10.1016\/j.apsb.2020.08.014"},{"key":"3277_CR7","doi-asserted-by":"publisher","first-page":"127377","DOI":"10.1016\/j.bmcl.2020.127377","volume":"30","author":"S Ullrich","year":"2020","unstructured":"Ullrich, S. & Nitsche, C. The SARS-CoV-2 main protease as drug target. Bioorg. Med Chem. Lett. 30, 127377 (2020).","journal-title":"Bioorg. Med Chem. Lett."},{"key":"3277_CR8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","volume":"582","author":"Z Jin","year":"2020","unstructured":"Jin, Z. et al. Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature 582, 289\u2013293 (2020).","journal-title":"Nature"},{"key":"3277_CR9","doi-asserted-by":"crossref","unstructured":"Cannalire, R., Cerchia, C., Beccari, A. R., Di Leva, F. S. & Summa, V. Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: state of the art and future opportunities. J. Med. Chem. 65, 27167\u20132746 (2020).","DOI":"10.1021\/acs.jmedchem.0c01140"},{"key":"3277_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4939-8976-8_1","volume":"1911","author":"DK Li","year":"2019","unstructured":"Li, D. K. & Chung, R. T. Overview of direct-acting antiviral drugs and drug resistance of hHepatitis C virus. Methods Mol. Biol. 1911, 3\u201332 (2019).","journal-title":"Methods Mol. Biol."},{"key":"3277_CR11","doi-asserted-by":"crossref","unstructured":"Alazard-Dany, N., Denolly, S., Boson, B. & Cosset, F. L. Overview of HCV life cycle with a special focus on current and possible future antiviral targets. Viruses 11, 30 (2019).","DOI":"10.3390\/v11010030"},{"key":"3277_CR12","first-page":"165","volume":"45","author":"XF Lu","year":"2010","unstructured":"Lu, X. F. & Chen, Z. W. The development of anti-HIV-1 drugs. Yao Xue Xue Bao 45, 165\u2013176 (2010).","journal-title":"Yao Xue Xue Bao"},{"key":"3277_CR13","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.tim.2016.03.010","volume":"24","author":"N Kurt Yilmaz","year":"2016","unstructured":"Kurt Yilmaz, N., Swanstrom, R. & Schiffer, C. A. Improving viral protease inhibitors to counter drug resistance. Trends Microbiol 24, 547\u2013557 (2016).","journal-title":"Trends Microbiol"},{"key":"3277_CR14","doi-asserted-by":"publisher","first-page":"165878","DOI":"10.1016\/j.bbadis.2020.165878","volume":"1866","author":"AAT Naqvi","year":"2020","unstructured":"Naqvi, A. A. T. et al. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. Biochim Biophys. Acta Mol. Basis Dis. 1866, 165878 (2020).","journal-title":"Biochim Biophys. Acta Mol. Basis Dis."},{"key":"3277_CR15","doi-asserted-by":"publisher","first-page":"13600","DOI":"10.1128\/JVI.78.24.13600-13612.2004","volume":"78","author":"BH Harcourt","year":"2004","unstructured":"Harcourt, B. H. et al. Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity. J. Virol. 78, 13600\u201313612 (2004).","journal-title":"J. Virol."},{"key":"3277_CR16","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1126\/science.1085658","volume":"300","author":"K Anand","year":"2003","unstructured":"Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J. R. & Hilgenfeld, R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 300, 1763\u20131767 (2003).","journal-title":"Science"},{"key":"3277_CR17","doi-asserted-by":"crossref","unstructured":"Amin, S. A., Banerjee, S., Ghosh, K., Gayen, S. & Jha, T. Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors. Bioorg. Med. Chem. 29, 115860 (2020).","DOI":"10.1016\/j.bmc.2020.115860"},{"key":"3277_CR18","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.pathol.2020.09.006","volume":"52","author":"AM Kaufer","year":"2020","unstructured":"Kaufer, A. M., Theis, T., Lau, K. A., Gray, J. L. & Rawlinson, W. D. Laboratory biosafety measures involving SARS-CoV-2 and the classification as a Risk Group 3 biological agent. Pathology 52, 790\u2013795 (2020).","journal-title":"Pathology"},{"key":"3277_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21630-5","volume":"12","author":"E Heilmann","year":"2021","unstructured":"Heilmann, E. et al. Chemogenetic ON and OFF switches for RNA virus replication. Nat. Commun. 12, 1362 (2021).","journal-title":"Nat. Commun."},{"key":"3277_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1006\/smvy.1997.0105","volume":"8","author":"CR Pringle","year":"1997","unstructured":"Pringle, C. R. & Easton, A. J. Monopartite negative strand RNA genomes. Semin Virol. 8, 49\u201357 (1997).","journal-title":"Semin Virol."},{"key":"3277_CR21","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1073\/pnas.73.5.1504","volume":"73","author":"G Abraham","year":"1976","unstructured":"Abraham, G. & Banerjee, A. K. Sequential transcription of the genes of vesicular stomatitis virus. Proc. Natl Acad. Sci. USA 73, 1504\u20131508 (1976).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3277_CR22","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1073\/pnas.73.2.442","volume":"73","author":"LA Ball","year":"1976","unstructured":"Ball, L. A. & White, C. N. Order of transcription of genes of vesicular stomatitis virus. Proc. Natl Acad. Sci. USA 73, 442\u2013446 (1976).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3277_CR23","doi-asserted-by":"crossref","unstructured":"Heilmann, E. et al. The methyltransferase region of vesicular stomatitis virus L polymerase is a target site for functional intramolecular insertion. Viruses 11, 989 (2019).","DOI":"10.3390\/v11110989"},{"key":"3277_CR24","doi-asserted-by":"publisher","first-page":"11750","DOI":"10.1128\/JVI.01371-15","volume":"89","author":"TK Soh","year":"2015","unstructured":"Soh, T. K. & Whelan, S. P. Tracking the fate of genetically distinct vesicular stomatitis virus matrix proteins highlights the role for late domains in assembly. J. Virol. 89, 11750\u201311760 (2015).","journal-title":"J. Virol."},{"key":"3277_CR25","doi-asserted-by":"publisher","first-page":"6368","DOI":"10.1128\/JVI.00211-06","volume":"80","author":"SC Das","year":"2006","unstructured":"Das, S. C., Nayak, D., Zhou, Y. & Pattnaik, A. K. Visualization of intracellular transport of vesicular stomatitis virus nucleocapsids in living cells. J. Virol. 80, 6368\u20136377 (2006).","journal-title":"J. Virol."},{"key":"3277_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jviromet.2018.01.003","volume":"254","author":"K Konduru","year":"2018","unstructured":"Konduru, K., Shurtleff, A. C., Bavari, S. & Kaplan, G. High degree of correlation between Ebola virus BSL-4 neutralization assays and pseudotyped VSV BSL-2 fluorescence reduction neutralization test. J. Virol. Methods 254, 1\u20137 (2018).","journal-title":"J. Virol. Methods"},{"key":"3277_CR27","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s00109-012-0863-6","volume":"90","author":"A Muik","year":"2012","unstructured":"Muik, A. et al. Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy. J. Mol. Med. (Berl., Ger.) 90, 959\u2013970 (2012).","journal-title":"J. Mol. Med. (Berl., Ger.)"},{"key":"3277_CR28","doi-asserted-by":"crossref","unstructured":"Miczi, M. et al. Identification of host cellular protein substrates of SARS-COV-2 main protease. Int. J. Mol. Sci. 21, 9523 (2020).","DOI":"10.3390\/ijms21249523"},{"key":"3277_CR29","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","volume":"583","author":"DE Gordon","year":"2020","unstructured":"Gordon, D. E. et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583, 459\u2013468 (2020).","journal-title":"Nature"},{"key":"3277_CR30","doi-asserted-by":"publisher","first-page":"12997","DOI":"10.1073\/pnas.1601327113","volume":"113","author":"T Muramatsu","year":"2016","unstructured":"Muramatsu, T. et al. SARS-CoV 3CL protease cleaves its C-terminal autoprocessing site by novel subsite cooperativity. Proc. Natl. Acad. Sci. USA 113, 12997\u201313002 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3277_CR31","doi-asserted-by":"publisher","first-page":"31257","DOI":"10.1074\/jbc.M502577200","volume":"280","author":"MF Hsu","year":"2005","unstructured":"Hsu, M. F. et al. Mechanism of the maturation process of SARS-CoV 3CL protease. J. Biol. Chem. 280, 31257\u201331266 (2005).","journal-title":"J. Biol. Chem."},{"key":"3277_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18233-x","volume":"11","author":"L Fu","year":"2020","unstructured":"Fu, L. et al. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nat. Commun. 11, 4417 (2020).","journal-title":"Nat. Commun."},{"key":"3277_CR33","doi-asserted-by":"publisher","unstructured":"Su, H. et al. Discovery of baicalin and baicalein as novel, natural product inhibitors of SARS-CoV-2 3CL protease in vitro. bioRxiv https:\/\/doi.org\/10.1101\/2020.04.13.038687 (2020).","DOI":"10.1101\/2020.04.13.038687"},{"key":"3277_CR34","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41594-020-0440-6","volume":"27","author":"Z Jin","year":"2020","unstructured":"Jin, Z. et al. Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. Nat. Struct. Mol. Biol. 27, 529\u2013532 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"3277_CR35","doi-asserted-by":"publisher","unstructured":"Li, X. et al. Ethacridine inhibits SARS-CoV-2 by inactivating viral particles in cellular models. bioRxiv https:\/\/doi.org\/10.1101\/2020.10.28.359042 (2020).","DOI":"10.1101\/2020.10.28.359042"},{"key":"3277_CR36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s42003-020-01577-x","volume":"4","author":"V Mody","year":"2021","unstructured":"Mody, V. et al. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. Commun. Biol. 4, 93 (2021).","journal-title":"Commun. Biol."},{"key":"3277_CR37","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1126\/science.abg5827","volume":"373","author":"N Drayman","year":"2021","unstructured":"Drayman, N. et al. Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. Science 373, 931\u2013936 (2021).","journal-title":"Science"},{"key":"3277_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26239-2","volume":"12","author":"B Boras","year":"2021","unstructured":"Boras, B. et al. Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19. Nat. Commun. 12, 6055 (2021).","journal-title":"Nat. Commun."},{"key":"3277_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-79357-0","volume":"10","author":"JC Ferreira","year":"2020","unstructured":"Ferreira, J. C. & Rabeh, W. M. Biochemical and biophysical characterization of the main protease, 3-chymotrypsin-like protease (3CLpro) from the novel coronavirus SARS-CoV 2. Sci. Rep. 10, 22200 (2020).","journal-title":"Sci. Rep."},{"key":"3277_CR40","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1517\/17460441.3.6.671","volume":"3","author":"N Green","year":"2008","unstructured":"Green, N., Ott, R. D., Isaacs, R. J. & Fang, H. Cell-based assays to identify Iinhibitors of viral disease. Expert Opin. Drug Disco. 3, 671\u2013676 (2008).","journal-title":"Expert Opin. Drug Disco."},{"key":"3277_CR41","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-020-2294-9","volume":"582","author":"T Thi Nhu Thao","year":"2020","unstructured":"Thi Nhu Thao, T. et al. Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform. Nature 582, 561\u2013565 (2020).","journal-title":"Nature"},{"key":"3277_CR42","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/14756366.2020.1850710","volume":"36","author":"WC Chiou","year":"2021","unstructured":"Chiou, W. C. et al. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors. J. Enzym. Inhib. Med Chem. 36, 147\u2013153 (2021).","journal-title":"J. Enzym. Inhib. Med Chem."},{"key":"3277_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijbiomac.2021.02.012","volume":"176","author":"A Du","year":"2021","unstructured":"Du, A. et al. Epigallocatechin-3-gallate, an active ingredient of traditional Chinese medicines, inhibits the 3CLpro activity of SARS-CoV-2. Int J. Biol. Macromol. 176, 1\u201312 (2021).","journal-title":"Int J. Biol. Macromol."},{"key":"3277_CR44","doi-asserted-by":"crossref","unstructured":"Froggatt, H. M., Heaton, B. E. & Heaton, N. S. Development of a fluorescence-based, high-throughput SARS-CoV-2 3CL(pro) reporter assay. J. Virol 94, e01265\u2013e012320 (2020).","DOI":"10.1128\/JVI.01265-20"},{"key":"3277_CR45","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12985-020-01457-0","volume":"17","author":"M Mahdi","year":"2020","unstructured":"Mahdi, M. et al. Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2\u2019s main protease. Virol. J. 17, 190 (2020).","journal-title":"Virol. J."},{"key":"3277_CR46","doi-asserted-by":"publisher","unstructured":"Moghadasi, S. A. et al. Gain-of-function assay for SARS-CoV-2 M (pro) inhibition in living cells. bioRxiv https:\/\/doi.org\/10.1101\/2020.11.09.375139 (2020).","DOI":"10.1101\/2020.11.09.375139"},{"key":"3277_CR47","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"DR Owen","year":"2021","unstructured":"Owen, D. R. et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science 374, 1586\u20131593 (2021).","journal-title":"Science"},{"key":"3277_CR48","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1128\/jvi.70.4.2318-2323.1996","volume":"70","author":"MJ Schnell","year":"1996","unstructured":"Schnell, M. J., Buonocore, L., Whitt, M. A. & Rose, J. K. The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J. Virol. 70, 2318\u20132323 (1996).","journal-title":"J. Virol."},{"key":"3277_CR49","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.1158\/0008-5472.CAN-13-3306","volume":"74","author":"A Muik","year":"2014","unstructured":"Muik, A. et al. Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency. Cancer Res 74, 3567\u20133578 (2014).","journal-title":"Cancer Res"},{"key":"3277_CR50","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nmeth.1318","volume":"6","author":"DG Gibson","year":"2009","unstructured":"Gibson, D. G. et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. methods 6, 343\u2013345 (2009).","journal-title":"Nat. methods"},{"key":"3277_CR51","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/gt.2011.38","volume":"18","author":"T Aoki","year":"2011","unstructured":"Aoki, T., Miyauchi, K., Urano, E., Ichikawa, R. & Komano, J. Protein transduction by pseudotyped lentivirus-like nanoparticles. Gene Ther. 18, 936\u2013941 (2011).","journal-title":"Gene Ther."},{"key":"3277_CR52","doi-asserted-by":"publisher","first-page":"10074","DOI":"10.1128\/JVI.74.21.10074-10080.2000","volume":"74","author":"U O\u2019Doherty","year":"2000","unstructured":"O\u2019Doherty, U., Swiggard, W. J. & Malim, M. H. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J. Virol. 74, 10074\u201310080 (2000).","journal-title":"J. Virol."},{"key":"3277_CR53","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/108705719900400206","volume":"4","author":"JH Zhang","year":"1999","unstructured":"Zhang, J. H., Chung, T. D. & Oldenburg, K. R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen 4, 67\u201373 (1999).","journal-title":"J. Biomol. Screen"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-022-03277-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-022-03277-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-022-03277-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T08:48:49Z","timestamp":1669366129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-022-03277-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,27]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3277"],"URL":"https:\/\/doi.org\/10.1038\/s42003-022-03277-0","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,27]]},"assertion":[{"value":"18 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.v.L. is founder of ViraTherapeutics GmbH. D.v.L serves as a scientific advisor to Boehringer Ingelheim and Pharma KG. E.H. and D.v.L have received an Austrian Science Fund (FWF) grant in the special call \u201cSARS urgent funding\u201d. RSH is the Margaret Harvey Schering Land Grant Chair for Cancer Research, a Distinguished McKnight University Professor, and an Investigator of the Howard Hughes Medical Institute. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"391"}}